A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)

Part of paid clinical trials in Glendale, California.

Sponsor
Angitia Incorporated Limited
Study ID
NCT07361354
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Participants
  • Pharmacokinetic Study

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • AGA2118 — DRUG
    Participants will receive AGA2118 administered by subcutaneous injection

Study Details

This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants

Key Dates

Start date
Jan 5, 2026
Status verified
Jan 2026
Primary completion
Jun 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1 (Japanese)
    One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of low dose AGA2118.
  • Experimental: Cohort 2 (Japanese)
    One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of medium dose AGA2118.
  • Experimental: Cohort 3 (Japanese)
    One of three single ascending dose cohorts of healthy Japanese participants. Participants will receive a single administration of high dose AGA2118.
  • Experimental: Cohort 4 (Caucasian)
    Healthy Caucasian participants will receive a single administration of high dose AGA2118.
  • Experimental: Cohort 5 (Chinese)
    Healthy Chinese participants will receive a single administration of high dose AGA2118.

Primary Outcome Measure

Maximum concentration (Cmax) [ Time Frame: Day 1 to up to the end of study (85 days post-dose) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Los Angeles EPCUGlendaleCalifornia91206
Stephanie Gill
[email protected]
888-228-7425
Esther Yoon (PRINCIPAL_INVESTIGATOR)

Find similar trials in Glendale, CA

By research site
Los Angeles EPCU· Glendale, CA

Related Studies